The Lonza Board of Directors announced the nomination of Stephen Fry as an Independent Member of the Board. Subject to his election at the Lonza Group Annual General Meeting in May 2026, Fry will also be appointed a member of the People and Governance Committee and the Audit and Compliance Committee.
Fry brings deep pharmaceutical industry experience, a global leadership perspective and strong expertise to the Board. He spent more than three decades at Eli Lilly and Company, where he held a broad range of international, operational and executive leadership roles, ultimately serving as Executive Vice President and Chief Human Resources Officer for 12 years. In this role, he led large-scale organizational transformation, shaped high-performance cultures and helped navigate the company through significant change.
Jean-Marc Huet, Chairman of the Board at Lonza, commented that Fry brings extensive international experience, combined with a strong track record in organizational governance, succession planning and people strategy development. "Stephen will play an important role in helping develop and embed our performance culture. This will support our ambition to attract and retain world-leading talent and bring our high-performing teams to the next level," Huet stated.
The nomination comes as Lonza, the world's largest contract development and manufacturing organization dedicated to serving the healthcare industry, continues to expand its global operations. The company works across five continents with approximately 20,000 colleagues who work alongside pharma and biotech companies to turn breakthrough innovations into viable therapies. Lonza generated sales of CHF 6.5 billion with a CORE EBITDA of CHF 2.1 billion in Full-Year 2025. More information about the company's operations and services can be found at https://www.lonza.com.
For business and technology leaders in the healthcare and pharmaceutical sectors, this board nomination signals Lonza's continued focus on strengthening its governance and organizational capabilities. Fry's extensive experience at Eli Lilly, particularly in human resources and organizational transformation during periods of significant industry change, suggests Lonza is preparing for continued growth and evolution in the competitive CDMO landscape. His appointment to both the People and Governance Committee and the Audit and Compliance Committee indicates the company is prioritizing both talent management and regulatory compliance as key strategic areas.
The pharmaceutical industry is undergoing rapid transformation with increasing demand for contract manufacturing services, particularly in biologics and cell and gene therapies. Lonza's move to bring in board-level expertise with deep industry knowledge and transformation experience suggests the company is positioning itself to navigate this evolving landscape effectively. Fry's background in building high-performance cultures could prove particularly valuable as Lonza competes for specialized talent in the highly competitive biotechnology sector.
Investors and industry observers will be watching how Fry's expertise in organizational development and governance might influence Lonza's strategic direction, particularly as the company continues to serve pharma and biotech companies working to bring life-saving and life-enhancing treatments to patients worldwide. The nomination reflects the increasing importance of board-level expertise in organizational culture and talent management within technology-driven healthcare companies.
